Literature DB >> 11342768

Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.

R H Hruban1, N V Adsay, J Albores-Saavedra, C Compton, E S Garrett, S N Goodman, S E Kern, D S Klimstra, G Klöppel, D S Longnecker, J Lüttges, G J Offerhaus.   

Abstract

Proliferative epithelial lesions in the smaller caliber pancreatic ducts and ductules have been the subject of numerous morphologic, clinical, and genetic studies; however, a standard nomenclature and diagnostic criteria for classifying these lesion have not been established. To evaluate the uniformity of existing systems for grading duct lesions in the pancreas, 35 microscopic slides with 35 representative duct lesions were sent to eight expert pathologists from the United States, Canada, and Europe. Kappa values for interobserver agreement could not be calculated initially because more than 70 different diagnostic terms were used by the eight pathologists. In several cases, the diagnoses rendered for a single duct lesion ranged from "hyperplasia," to "metaplasia," to "dysplasia," to "carcinoma in situ." This review therefore demonstrated the need for a standard nomenclature and classification system. Subsequently, during a working group meeting, the pathologists agreed to adopt a single standard system. The terminology pancreatic intraepithelial neoplasia (or PanIN) was selected, and diagnostic criteria for each grade of PanIN were established (http://pathology.jhu.edu/pancreas_panin). This new system was then evaluated by having the eight pathologists rereview the original 35 cases. Only seven different diagnoses were rendered, and kappa values of 0.43, 0.14, and 0.42 were obtained for PanINs 1, 2, and 3 respectively. Cases assigned other diagnoses (e.g., squamous metaplasia) collectively had a kappa value of 0.41. These results show both the potential of the classification system, and also the difficulty of classifying these lesions even with a consistent nomenclature. However, even when there is lack of consensus, having a restricted set of descriptions and terms allows a better understanding of the reasons for disagreement. It is suggested that we adopt and apply this system uniformly, with continued study of its reliability and use, and possibly further refinement. The acceptance of a standard classification system will facilitate the study of pancreatic duct lesions, and will lead ultimately to a better understanding of their biologic importance.

Entities:  

Mesh:

Year:  2001        PMID: 11342768     DOI: 10.1097/00000478-200105000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  338 in total

1.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  Acinar-to-ductal metaplasia in pancreatic cancer development.

Authors:  Roland M Schmid
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  Bronchiolar columnar cell dysplasia--genetic analysis of a novel preneoplastic lesion of peripheral lung.

Authors:  Reinhard Ullmann; Massimo Bongiovanni; Iris Halbwedl; Susanna Petzmann; Margit Gogg-Kammerer; Anna Sapino; Mauro Papotti; Gianni Bussolati; Helmut H Popper
Journal:  Virchows Arch       Date:  2003-04-09       Impact factor: 4.064

4.  Staining protocols for human pancreatic islets.

Authors:  Martha L Campbell-Thompson; Tiffany Heiple; Emily Montgomery; Li Zhang; Lynda Schneider
Journal:  J Vis Exp       Date:  2012-05-23       Impact factor: 1.355

5.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 6.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

Review 7.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

Review 9.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

10.  KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

Authors:  Alexandros Tzatsos; Polina Paskaleva; Francesco Ferrari; Vikram Deshpande; Svetlana Stoykova; Gianmarco Contino; Kwok-Kin Wong; Fei Lan; Patrick Trojer; Peter J Park; Nabeel Bardeesy
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.